The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Fixed-duration dose-reduced ibrutinib plus venetoclax: importance of toxicity reduction in CLL
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, comments on the importance of managing adverse events associated with novel therapies, particularly BTK inhibitors. Dr Ghia highlights that the TAILOR (NCT05963074) study proposes a proactive approach to mitigating cardiovascular events in patients with chronic lymphocytic leukemia (CLL) receiving dose-reduced fixed-duration ibrutinib plus venetoclax in the frontline setting. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
